BioStock: SynAct Pharma’s CSO and CMO comment on clinical development
SynAct Pharma continues to make progress in the development of the anti-inflammatory drug candidate AP1189. The company recently announced that AP1189 can be dosed for three months in future clinical studies, supported by preclinical toxicology results. Also, SynAct has now formulated AP1189 as a tablet – which is another big step for future clinical development. By the end of November, SynAct Pharma expects to present key results from BEGIN, a clinical phase IIa study in the primary indication rheumatoid arthritis. BioStock reached out to the company’s CSO Thomas Jonassen and CMO Anders Dyhr Toft for a comment.
Read the interview at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se